Atezolizumab Monotherapy and Consequent Therapy With Atezolizumab Plus Bevacizumab for NSCLC
Status:
Unknown status
Trial end date:
2020-06-30
Target enrollment:
Participant gender:
Summary
This is a single-arm phase II trial to evaluate the efficacy and safety of atezolizumab and
bevacizumab combination therapy (stage 2) after radiologic progression of atezolizumab
monotherapy (stage 1) in Korean patients with locally advanced or metastatic NSCLC who have
progressed during or following a platinum-containing regimen. Initially, patients will be
treated with Atezolizumab 1200mg every 3 weeks as a single agent (stage 1). After radiologic
progression from atezolizumab monotherapy, patients will be consequently treated with
atezolizumab (1200mg every 3 weeks) and combination with bevacizumab (15mg/kg every 3 weeks).
Exploratory biomarkers will be observed in order to identify predictive biomarkers correlated
to response and to evaluate the changes of local and systemic immune profile between baseline
and at the time of progression.